Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2025-06-17
- Target Recruit Count
- 54
- Registration Number
- NCT06719973
- Locations
- 🇯🇵
National Cancer Center Hospital - Dept of Respiratory Medicine, Chuo-ku, Japan
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC)
- First Posted Date
- 2025-05-05
- Last Posted Date
- 2025-05-12
- Lead Sponsor
- Merck Healthcare KGaA
- Target Recruit Count
- 51
- Registration Number
- 2024-517818-15-00
- Locations
- 🇦🇹
Medical University Of Vienna, Vienna, Austria
🇦🇹Ordensklinikum Linz GmbH, Linz, Austria
🇫🇷Hopital Saint Antoine, Paris Cedex 12, France
Anti-GD2 ADC M3554 in Advanced Solid Tumors
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-06-15
- Target Recruit Count
- 52
- Registration Number
- NCT06641908
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc, New York, New York, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
M9466 in Combination with Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
- Conditions
- Advanced solid tumors and colorectal cancer
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Merck Healthcare KGaA
- Target Recruit Count
- 13
- Registration Number
- 2024-514155-15-00
- Locations
- 🇪🇸
Hospital Quironsalud Barcelona, Barcelona, Spain
🇪🇸Hospital Universitario Quironsalud Madrid, Pozuelo De Alarcon, Spain
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2025-02-03
- Target Recruit Count
- 60
- Registration Number
- NCT06433219
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai PRIME - Mount Sinai - PRIME, New York, New York, United States
🇦🇺Liverpool Hospital - PARENT, Liverpool, Australia
Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 70
- Registration Number
- NCT06424717
- Locations
- 🇺🇸
Please Contact U.S. Medical Information, Rockland, Massachusetts, United States
🇩🇪Please Contact the Communication Center, Darmstadt, Germany
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2025-06-15
- Target Recruit Count
- 96
- Registration Number
- NCT06421935
- Locations
- 🇦🇺
GenesisCare North Shore (Oncology), St Leonards, Australia
🇺🇸NEXT Oncology - PARENT, New York, New York, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-07-18
- Target Recruit Count
- 18
- Registration Number
- NCT06056310
- Locations
- 🇺🇸
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Karmanos Cancer Institute - PARENT, Detroit, Michigan, United States
🇺🇸Montefiore Medical Center PRIME, Bronx, New York, United States
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2025-01-27
- Target Recruit Count
- 180
- Registration Number
- NCT05882734
- Locations
- 🇺🇸
UCLA Hematology and Oncology - Santa Monica, Santa Monica, California, United States
🇺🇸UPMC Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Tennessee Cancer Specialists - Biomedical Research, Knoxville, Tennessee, United States
Study of M5049 in DM and PM Participants (NEPTUNIA)
- Conditions
- PolymyositisDermatomyositis
- Interventions
- Drug: PlaceboDrug: M5049 high dose
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-06-17
- Target Recruit Count
- 40
- Registration Number
- NCT05650567
- Locations
- 🇺🇸
Neuromuscular Research Center, Phoenix, Arizona, United States
🇺🇸HonorHealth Research Institute - Bob Bove Neuroscience Institute-Neuroscience Research, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic Scottsdale (6365), Scottsdale, Arizona, United States